D espite the experience, plethora of trials, and multiple publications on its use, the best approach for initial warfarin dosing remains unclear. Several approaches have attempted to simplify what is, in reality, a very complex process influenced by a multitude of variable, frequently unpredictable, factors. Clinical dosing tools such as the nomogram reported by Roberts et al. 1 can have potential benefits if used correctly (and proven effective) in certain situations. Unfortunately, simplification of significant influencing factors creates limitations that, if unrecognized, can lead to suboptimal care.
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Initial warfarin dosing approaches have been under constant evaluation and revision since availability of the drug many decades ago. The initial 20-to 40-mg loading doses to achieve rapid anticoagulation gave way to smaller, 10mg "mini-loading" doses. These smaller loading doses have also been challenged as excessive, resulting in even lower initial dosing approaches. 2,3 Part of this transition is attributed to increased understanding of warfarin's variable pharmacokinetic and pharmacodynamic properties and improved methods for measuring its dose response. This includes the development of the international normalized ratio (INR). 4 The INR allowed a worldwide anticoagulation intensity standard for clinicians to compare informa-tion and use resultant data to develop and evaluate warfarin dosing approaches. Retrospective INR results also identified the large variables in measured dose response that occurred prior to its inception. Despite this, optimal approaches to achieve initial, safe anticoagulation with warfarin are still a matter of much debate.
The variability and difficulties in predicting warfarin dose response are seeded in the complexities surrounding it. This includes, but is not limited to, multiple active isomers, variables in metabolism, INR response, and drug interactions, as well as other unique inter/intrapatient sensitivity factors. For metabolism, several variants to the major enzyme (CYP2C9) responsible for transformation of warfarin have been identified. The presence of certain polymorphisms (CYP2C9*2, CYP2C9*3) has been associated with risks of increased sensitivity to warfarin elimination and over-anticoagulation. 5-7 These polymorphisms can be found in historically isolated populations as well. 8 Other factors altering warfarin's dose responses include hepatic or cardiac failure, concurrent infections, serum albumin level, impaired nutrition, stress, diarrhea, vitamin K intake, concurrent interacting drugs or herbs, thyroid function, acute illness, race, and age. 2,7,9,10 Although more consistent over previous methods, some variability in reported results still exists between thromboplastins used to measure the INR. The target INR range (usually 2-3) is also based on interpretation of the available literature, and deviations may be necessary in certain situations. Thus, each patient's warfarin dose and response are still subject to the presence of multiple and variable clinical factors.
In their article describing the assessment of an age-related warfarin initiation protocol, Roberts et al. describe an approach to initiating warfarin therapy based on the Fennerty nomogram adjusted to accommodate older patients. 1,11 Age has been suggested to be a factor for increased bleeding risks and increased sensitivity to war-farin. 2 After 4 days, 63% of their patients had attained a "stable" INR, which they defined as 2 consecutive results in the 2-3 range. However, an INR of 2.0 and then 3.0 the next day may not represent stability. In favor of their protocol, only 7% of the patients experienced INR values >4. The authors themselves admit that no common factor was notable in the over-target patients to explain the increased sensitivity. For the complete group, only 16% had noted concurrent increased sensitivity risk factors. Could part of this be explained by unidentified influencing factors?
The authors also state, "the key to warfarin initiation is not a matter of knowing the correct dose to begin with, but knowing how to respond to a change in the INR." While using the INR to determine a warfarin dose is critical, we must not forget patients' individual needs. Relying solely on the INR for dosing adjustments could result in compromised patient care. Part of their outcome is based on achieving an INR in the therapeutic range earlier than otherwise expected. What is not clear is the impact on outcomes when achieving earlier therapeutic INR values. Of the 73 patients in their study, only half had either a deepvein thrombosis (DVT) or pulmonary embolus. The rest, including 19% with atrial fibrillation, had other indications for anticoagulation. For atrial fibrillation, the positive benefits of oral anticoagulation seen in the various atrial fibrillation trials were not seen acutely, but over prolonged periods of time. 12-14 As noted by Roberts et al., unless certain high cardioembolic risk factors for stroke are present, such as poor cardiac chamber flow, observed thrombus on echo, and history of strokes, then aggressive loading doses of warfarin in atrial fibrillation may not be necessary.
True outcomes of different anticoagulation approaches and resultant intensities during initial therapy are also unclear. The INR represents a reduction in several vitamin K-dependent clotting factors. The international sensitivity index used to calculate an INR is based on approximately 6 weeks of stable warfarin dosing. 15 Early increasing values also relate more to factor VII reduction (and concurrent protein C reduction) and do not accurately represent the dynamic degree of anticoagulation. 3 Thus, how reliable is achieving an early INR within the therapeutic range in measuring anticoagulant effectiveness? The real antithrombic effects seen with factor II reduction may not occur for several days. This is part of the sixth American College of Chest Physicians (ACCP) Consensus Conference on Antithrombic Therapy position that recommends a continuation of heparin treatment until 2 INR measurements drawn 24 hours apart have been in the therapeutic range. 2 The certainty of overlapping therapy is questioned from one study looking at outcomes of recurrent thromboembolism depending on duration of heparin therapy in 36 924 courses. No difference in recurrent thromboembolism with hospital stays of 3 versus 5 days (prior to lowmolecular-weight heparin [LMWH] availability) was seen, suggesting that as few as 3 days of intravenous heparin overlapping with warfarin may provide effective initial treatment for DVT. 16 Although Roberts et al.'s proposed nomogram does achieve INR values in the therapeutic range in 86% of patients by 6 days with minimal overshooting, details on heparin therapy and long-term followup were not stated. The protocol design used the nomogram for the first 4 days and follow-up only up to day 6. No comparison group was used to measure the nomogram's impact. 1 Even though the first days of dosing can be the most difficult to identify longer maintenance doses, the real outcome or impact of their approach is unknown.
Is there a best approach to initiating warfarin? The present sixth ACCP Consensus Conference on Antithrombic Therapy position on loading doses (defined as more than the expected average maintenance dose) is that it is unnecessary in most patients. 2 They suggest starting with an average maintenance dose of 5 mg. Part of this is based on the observations of Harrison et al. 3 in a small group of patients. An initial dose of 5 mg (n = 25) compared with 10 mg (n = 25), with subsequent doses based on a nomogram, resulted in achieving INR values between 2-3 at 3 1 /2 days in 19 and 15 patients, respectively. Two patients in the 5-mg and 3 patients in the 10-mg group had values >3.0 at that time. Factor VII and protein C levels were concurrently measured and their decline was linear; protein C declined more rapidly in the initial 10-mg dose group. This finding, in theory, supports the possibility that initial higher loading doses could produce a hypercoagulable state if no other anticoagulant such as heparin or an LMWH is concurrently used. Unfortunately, safety and efficacy of their approach over a prolonged period of time in a larger sample was not evaluated.
Another nomogram was recently tested in initiating warfarin in 105 outpatients after a 2-day loading period with follow-up INR values on days 3, 5, and 8. 17 Eighty-three percent of the INRs were therapeutic by day 5, and 98% by day 8. Six INR values >4.5 were noted. Using 155 patients, this same group compared their nomogram using a 10-mg initial dose with the 5-mg approach described by Harrison et al. 3 The mean time for a therapeutic INR occurred earlier in the 10-mg (88.2%) than in the 5-mg (33.3%) initial dose group in the therapeutic range by day 5. 18 Results with analysis of bleeding and clot formation will be published soon. Gedge et al. 19 also compared an age-modified Fennerty regimen (different from the Roberts et al. approach) in elderly patients with a low-dose warfarin induction method. Both groups started with a 10-mg dose, with the low-dose warfarin regimen arm having slightly lower doses on subsequent days. Time to therapeutic INR was longer in the low-dose group, but more time in the therapeutic range was observed, with fewer INR results >4.5. However, ability to predict a maintenance regimen within 1 mg by day 8 (55% of patients) was the same for both groups. For patients not requiring emergent anticoagulation, another study found that stable initial doses (i.e., 5 mg) over several days may provide an easy method to predict the long-term maintenance dose in atrial fibrillation. 20 However, only 61 of the 105 initial candidates could be evaluated, the rest being excluded for associated interfering drugs, increased baseline INR >1.2, presence of dilated cardiomyopathy, or inability to reach stable anticoagulation. These factors further illustrate how exclusive these approaches can be. Targeting one specific dose can have limitations. In a patient with multiple sensitivity factors or elevated baseline coagulation values, 5 mg could represent a very aggressive loading dose. For individuals ultimately requiring larger maintenance doses (>5 mg), lower doses may result in an undesirable delay to reach target INR values, especially when patients are eager to go home, or when economic pressures and shortage of resources encourage the shortest possible hospital stay or duration of "bridging" cross cover with a rapid-acting anticoagulant. One could also argue a more conservative initial dosing approach when "bridging" with an LMWH or indirect Xa inhibitor while initiating warfarin therapy. Logistics and timing may be important determinants, especially in the outpatient setting where close follow-up evaluations have some limitations. To avoid the initial "one dose for all" approach, which, as noted, has limitations, nomograms and computer-assisted dosing have been suggested. 11,17,21 Results have suggested potential advantages when used by practitioners who do not routinely manage warfarin therapy. 21 These tools are limited by the selected patient variables incorporated into their design. Another successful approach has been dosing and monitoring by dedicated anticoagulation clinics. Those clinics have been associated with reduced thrombosis and bleeding complications for patients receiving warfarin. 2 Here, practitioners familiar with the presence of multiple variables (stable or unstable) can incorporate their significance when developing anticoagulation plans specific to each patient's needs.
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Impacts of inpatient specialty programs have also been reported. 22,23 Previously, we compared the impact of a pharmacist consultation with a matched physician cohort on initiating warfarin in 60 inpatients with no prior history of warfarin use. 23 Initial dosing recommendations (the physician made the final dose decision) were based on careful assessment of each patient's clinical presentation (e.g., concurrent medical problems, drug interactions) and anticoagulation goals. Mean initial doses on days 1 through 4 were 8.3 ± 3.0 mg, 7.6 ± 2.9 mg, 5.5 ± 2.9 mg, and 4.0 ± 2.4 mg, respectively. Fourteen INR values >3.5 were noted between days 3 and 5, and 3 were >6.0. All the INR values >6 were from 10-mg initial doses for 2-3 days despite initial recommendations for lower initial doses. Of the 60 patients dosed in this manner, the mean time to INR >2.0 was 3.0 ± 1.3 days; only 3 of the 60 patients required >4 days to achieve that goal. Follow-up at 3 months actually showed a reduction in bleeding and thrombosis in the consultation group. One must recognize that any long-term outcomes are influenced by multiple variables beyond the initial doses.
Pressures to use loading doses may be seeded in the desire to achieve rapid anticoagulation so concurrent unfractionated heparin or LMWH therapy can be stopped, costly hospitalization time can be reduced, or the critical need exists to achieve early antithrombotic effects. Another possible argument in favor of loading doses is to identify an individual's sensitivity to a dose response earlier rather than later. Consider the situation of a sensitive delayed respon-der started on 5 mg and then discharged 4 days later when the INR reaches 2.0 (but could be still rising). Here the sensitivity may not be noted until the patient later presents with bleeding complications or an undesirable high value on follow-up. One trick we used is to place as much time between the initial doses and subsequent INRs to better identify the degree of dose response. Supporters of loading approaches could argue that initial loading doses may unmask such sensitivity while the patient is more closely followed. Roberts et al.'s protocol, to some extent, does accommodate this.
This still leaves the question of the optimal INR. The unique needs of an individual patient, such as coexistent hypercoagulable states or presence of certain artificial valve types, may have more optimal antithrombotic outcomes (after careful consideration of potential bleeding risks) when the INR target is between 2.5 and 3.0 or 3.5. 4,12,24,25 Nomograms may not directly address INR targets other than 2-3, and the user may need to "fudge" the dose. Higher targets can lead to more frequent, occasional INR values drifting into the >3-3.5 range, which may be undesirable and is associated with increased risk for bleeding and death. 26
Summary
Initiating warfarin in warfarin-naïve patients continues to be a clinical challenge. Present approaches require some degree of data extrapolation or assumptions to justify benefits. Use of LMWHs or indirect Xa inhibitors can ease the process for many patients, resulting in a smoother transition to warfarin or its avoidance altogether. Additional agents on the horizon, such as the oral direct thrombin inhibitor xi-melagatran, may provide even easier initiation of long-term anticoagulation therapy. Despite this, there will still be individuals requiring warfarin. Nomograms and computer-assisted programs can be useful aids, but by their limiting design, are situation specific. Thus, there is a need for validation in larger samples with control comparisons, clearly identifying any limitations. Their use should not completely replace a careful assessment of each patient's clinical presentation or anticoagulation needs, especially when these include physiologic factors, concurrent drug interactions, or other sensitivity factors that may not have been taken into consideration. Each patient should therefore be individually and carefully assessed for risks of bleeding or thrombosis and benefits of anticoagulation therapy.
The true degree of anticoagulation represented by an INR value must also be considered. Initial dosing plans should include these considerations and be adjusted with the tools and resources available to optimize therapy. No complete foolproof method that works for almost every patient is currently (and most likely not in the near future) available. When using adjunct nomograms, computer programs, or other tools to derive a warfarin dose prior to reaching steady-state, knowledge of their benefits and limitations should be incorporated into the final dose determination.
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